On Invalid Date, Pacira Biosciences (NASDAQ: PCRX) reported Q4 2023 earnings per share (EPS) of $0.54, up 345.45% year over year. Total Pacira Biosciences earnings for the quarter were $24.87 million. In the same quarter last year, Pacira Biosciences's earnings per share (EPS) was -$0.22.
As of Q2 2024, Pacira Biosciences's earnings has grown 160% year over year. This is 147.12 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 12.88%. Pacira Biosciences's earnings in the past year totalled $41.96 million.
What is PCRX's earnings date?
Pacira Biosciences's earnings date is Invalid Date. Add PCRX to your watchlist to be reminded of PCRX's next earnings announcement.
What was PCRX's revenue last quarter?
On Invalid Date, Pacira Biosciences (NASDAQ: PCRX) reported Q4 2023 revenue of $181.24 million up 5.4% year over year. In the same quarter last year, Pacira Biosciences's revenue was $171.96 million.
What was PCRX's revenue growth in the past year?
As of Q2 2024, Pacira Biosciences's revenue has grown 1.22% year over year. This is 8.75 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.98%. Pacira Biosciences's revenue in the past year totalled $674.98 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.